Jeremy Paull

Company: Starpharma Ltd.

Job title: VP Development and Regulatory Affairs

Seminars:

Expanding Radiopharmaceutical Targeting Mechanisms with Novel Moieties to Harness Enhanced Specificity, Efficacy & Safety 11:00 am

The development of novel targeting moieties for radiopharmaceuticals has seen significant advancements, particularly in the context of targeting cancer cells and supporting tissues. These novel moieties include small peptides, cyclic peptides, bispecifics and nanobodies, each offering unique advantages in terms of specificity, stability, and pharmacokinetics. Uncovering the latest understandings and developments across novel targeting approaches,…Read more

day: Workshop B